AUVELITY is a novel, oral, NMDA receptor antagonist with multimodal activity approved for the treatment of MDD in adults. AUVELITY is a proprietary extended-release oral tablet containing dextromethorphan HBr (45 mg) and bupropion HCl (105 mg). The dextromethorphan component of AUVELITY is an an...
(i) muscarinic acetylcholine receptors, and (ii) the kainate and AMPA classes of glutamate receptors, those safener drug combinations can provide exceptionally potent and reliable safening activity, which can enable the safe use of potent NMDA antagonist drugs for a number of highly beneficial ...
Dextromethorphan (DXM) is an over‐the‐counter drug that is commonly abused by teenagers. Its main pharmacological property is a low‐affinity N‐methyl‐d‐aspartate (NMDA) receptor antagonist. Case Presentation: We report acute psychotic dissociation induced by DXM and alcohol in a patient with...
The use of NMDA antagonist memantine in drug-resitant dyskinesia resulting from L-DOPA. Mov Disord 2000;15:1016-7.H. A. Hanagasi, G. Kaptanoglu, H. A. Sahin, and M. Emre, "The use of NMDA antagonist memantine in drug-resitant dyskinesia resulting from L-dopa," Movement Disorders, ...
Ketamine, an NMDAR antagonist, is a dissociative anaesthetic agent, and its effects include catalepsy, amnesia, and marked analgesia without loss of consciousness or muscle relaxation in patients [41]. Purposeless movements, increased muscle tone and resistance to passive motion have been observed ...
专利名称：Prolonged administration of NMDA antagonist drug and safener drug to create improved stable neural homeostasis 发明人：John W. Olney,Ronald E. Harbut,Graeme E.Correll,Patrick D. Kelly 申请号：US10786212 申请日：20040226 公开号：US20050222270A1 公开日：20051006 专利内容由知识产权出版社提供 ...
After 24 h the last threshold determination rats received a bilateral VM microinjection of the NMDA antagonist PPPA (0.825 nmol per 0.5 ml per side) and reward thresholds were measured again immediately after the injection for 120 min. siRNA and Drug Downregulation of selective NMDAR subunits was...
However, determination of NMDA receptor antagonist activity for norketamine indicated that this compound is 7–10 times less potent than ketamine (Far- ber and Olney, unpublished data), so that even terminal norketamine levels were unlikely to contribute signifi- cantly to any NRH-induced clinical ...
This drug system has anticonvulsant activity and can alleviate brain damage due to stroke. U.S. Pat. No. 6,653,354 (Franks et al.) discloses a method for reducing the level of NMDAR activation by use of the NMDA antagonist, xenon to inhibit synaptic plasticity. The xenon composition of ...
Down syndrome (DS) is the most common genetic cause of intellectual disability. TheN-methyl-D-aspartate (NMDA) receptor uncompetitive antagonist, memantine hydrochloride (memantine), has been shown to improve learning/memory and rescue one form of hippocampus synaptic plasticity dysfunction in the best...